{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["91"],"submitter":["Bogdanski AM"],"pubmed_abstract":["<h4>Background</h4>Individuals with Lynch syndrome (LS) are advised to undergo pancreatic ductal adenocarcinoma (PDAC) surveillance if their lifetime risk is ≥5%, however, evidence is limited. This study quantifies lifetime risk and survival of three cancers relevant to PDAC surveillance, including PDAC, ampullary carcinoma (AC) and distal cholangiocarcinoma (dCC), to evaluate whether surveillance is justified.<h4>Methods</h4>This retrospective nationwide Dutch cohort study included individuals with LS pathogenic variants (PVs) in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i> or <i>EpCAM</i> (identified between 1985 and 2024) and compared them to sporadic cases from the general population (diagnosed between 2000 and 2022). Cumulative incidence (CI) of PDAC, AC and dCC was estimated us"],"journal":["EClinicalMedicine"],"pagination":["103755"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828513"],"repository":["biostudies-literature"],"pubmed_title":["Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study."],"pmcid":["PMC12828513"],"pubmed_authors":["Appels MIE","Mundt MW","Hazen W","de Vos Tot Nederveen Cappel WH","Erkelens GW","Houben MHMG","Brosens LAA","van Lent AUG","Rondagh E","Collaborative investigators from the Dutch Foundation for Detection of Hereditary Tumors","Hazen ML","Bonsing BA","Dekker E","Geraedts A","Tang TJ","Nicolaas JS","Capelle LG","Tanis AA","Oort FA","Spaander MC","van Berkel AM","van Enckevort CCG","van Lier MGF","Terhaar Sive Droste JS","van Boekel M","Kerkhof M","van Vlerken L","Geesing J","Thijssen AY","Marsman WA","van der Geest LG","Smits ME","Andriessen R","Keller JJ","Koornstra JJ","Bigirwamungu-Bargeman M","Dekkers PEP","van Kouwen MCA","Zonneveld AM","van den Berg MW","Aktas H","De Filippi JP","Bogdanski AM","Nielsen M","de Kort S","van Heerde MJ","Ramsoekh D","Corporaal S","Ijspeert JEG","Boertien WE","Kuiper T","van Leerdam ME","Mulder SA","Schoon EJ","Hove WRT","Langers AMJ","Verhulst ML","Al-Toma A","Talstra NC","Postma C","Klatte DCF","Van Hooft JE","Borg FT","Voogd F","Verveer C","Thijs WJ","Leeuwenburgh I","van Rooij JE","Dutch Pancreatic Cancer Group","Meiland R","Bus PJ","Haans JJL"],"additional_accession":[]},"is_claimable":false,"name":"Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study.","description":"<h4>Background</h4>Individuals with Lynch syndrome (LS) are advised to undergo pancreatic ductal adenocarcinoma (PDAC) surveillance if their lifetime risk is ≥5%, however, evidence is limited. This study quantifies lifetime risk and survival of three cancers relevant to PDAC surveillance, including PDAC, ampullary carcinoma (AC) and distal cholangiocarcinoma (dCC), to evaluate whether surveillance is justified.<h4>Methods</h4>This retrospective nationwide Dutch cohort study included individuals with LS pathogenic variants (PVs) in <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i> or <i>EpCAM</i> (identified between 1985 and 2024) and compared them to sporadic cases from the general population (diagnosed between 2000 and 2022). Cumulative incidence (CI) of PDAC, AC and dCC was estimated us","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T22:31:08.268Z","creation":"2026-06-06T03:10:26.816Z"},"accession":"S-EPMC12828513","cross_references":{"pubmed":["41583364"],"doi":["10.1016/j.eclinm.2026.103755"]}}